Immunovant Balance Sheet

Financials in millions USD. Fiscal year is April - March.

Millions USD. Fiscal year is Apr - Mar.

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun '26 Jun 30, 2026	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Cash & Equivalents	797.8	902.11	713.97	635.37	376.53	493.82
Cash & Short-Term Investments	797.8	902.11	713.97	635.37	376.53	493.82
Cash Growth	33.21%	26.35%	12.37%	68.74%	-23.75%	23.41%
Accounts Receivable	0.7	1.13	2.08	5.34	0.7	12.23
Other Current Assets	52.68	45.58	51.61	25.07	27.1	6.89
Total Current Assets	851.18	948.82	767.66	665.77	404.33	512.93
Net Property, Plant & Equipment	0.35	0.52	0.94	0.6	1.51	2.63
Other Long-Term Assets	0.96	7.68	7.62	-	-	-
Total Assets	852.49	957.01	776.22	666.37	405.84	515.56
Accounts Payable	10.14	7.54	17.66	7.16	1.35	18.63
Accrued Expenses	106.96	96.63	50.75	41.3	40.42	24.58
Current Portion of Leases	-	0.07	0.1	0.14	1.17	1.15
Other Current Liabilities	-	0.18	0.27	0.02	0.35	0.17
Total Current Liabilities	117.1	104.42	68.78	48.61	43.3	44.52
Long-Term Leases	-	-	-	-	0.05	1.22
Total Long-Term Liabilities	-	-	-	-	0.05	1.22
Total Liabilities	117.1	104.42	68.78	48.61	43.34	45.74
Common Stock	0.02	0.02	0.02	0.01	0.01	0.01
Additional Paid-in Capital	2,633	2,597	1,945	1,442	927.98	824.8
Accumulated Other Comprehensive Income	0.73	0.73	1.46	1.91	0.85	0.4
Retained Earnings	-1,898	-1,745	-1,240	-825.68	-566.35	-355.39
Shareholders' Equity	735.39	852.59	707.45	617.76	362.49	469.83
Total Liabilities & Equity	852.49	957.01	776.22	666.37	405.84	515.56
Total Debt	-	0.07	0.1	0.14	1.22	2.36
Net Cash (Debt)	797.8	902.04	713.87	635.23	375.31	491.45
Net Cash Growth	33.21%	26.36%	12.38%	69.25%	-23.63%	23.88%
Net Cash Per Share	4.17	4.95	4.71	4.60	3.05	4.48
Book Value	735.39	852.59	707.45	617.76	362.49	469.83
Book Value Per Share	3.85	4.67	4.67	4.47	2.95	4.28
Tangible Book Value	735.39	852.59	707.45	617.76	362.49	469.83
Tangible Book Value Per Share	3.85	4.67	4.67	4.47	2.95	4.28

SEC Filings: 10-K · 10-Q